Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Targetability of STAT3-JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tract.

Hu G, Phillips JL, Dasari S, Jacobs HK, Luchtel RA, Oishi N, Hundal T, Ahmed NH, Satou A, Epstein AL, Bennani NN, Nowakowski GS, Murray JA, Feldman AL.

Leukemia. 2019 Dec 13. doi: 10.1038/s41375-019-0678-3. [Epub ahead of print] No abstract available.

PMID:
31836854
2.

Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia.

Zanwar S, Abeykoon JP, Durot E, King R, Perez Burbano GE, Kumar S, Gertz MA, Quinquenel A, Delmer A, Gonsalves W, Cornillet-Lefebvre P, He R, Warsame R, Buadi FK, Novak AJ, Greipp PT, Inwards D, Habermann TM, Micallef I, Go R, Muchtar E, Kourelis T, Dispenzieri A, Lacy MQ, Dingli D, Nowakowski G, Thompson CA, Johnston P, Thanarajasingam G, Bennani NN, Witzig TE, Villasboas J, Leung N, Lin Y, Kyle RA, Rajkumar SV, Ansell SM, Le-Rademacher JG, Kapoor P.

Am J Hematol. 2020 Mar;95(3):274-281. doi: 10.1002/ajh.25697. Epub 2019 Dec 31.

PMID:
31814157
3.

Bone marrow findings in Erdheim-Chester disease: increased prevalence of chronic myeloid neoplasms.

Goyal G, Ravindran A, Liu Y, He R, Shah MV, Bennani NN, Patnaik MM, Rech KL, Go RS; Mayo Clinic Histiocytosis Working Group.

Haematologica. 2020 Jan 31;105(2):e84-e86. doi: 10.3324/haematol.2019.234187. Print 2020. No abstract available.

4.

The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease.

Goyal G, Young JR, Koster MJ, Tobin WO, Vassallo R, Ryu JH, Davidge-Pitts CJ, Hurtado MD, Ravindran A, Sartori Valinotti JC, Bennani NN, Shah MV, Rech KL, Go RS; Mayo Clinic Histiocytosis Working Group.

Mayo Clin Proc. 2019 Oct;94(10):2054-2071. doi: 10.1016/j.mayocp.2019.02.023. Epub 2019 Aug 28.

PMID:
31472931
5.

Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.

Satou A, Bennani NN, Feldman AL.

Expert Rev Hematol. 2019 Oct;12(10):833-843. doi: 10.1080/17474086.2019.1647777. Epub 2019 Jul 31.

PMID:
31365276
6.

Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma.

Wang Y, Maurer MJ, Larson MC, Allmer C, Feldman AL, Bennani NN, Thompson CA, Porrata LF, Habermann TM, Witzig TE, Ansell SM, Slager SL, Nowakowski GS, Cerhan JR.

Br J Haematol. 2019 Sep;186(6):820-828. doi: 10.1111/bjh.15997. Epub 2019 May 28.

PMID:
31135975
7.

Recurrent MSC E116K mutations in ALK-negative anaplastic large cell lymphoma.

Luchtel RA, Zimmermann MT, Hu G, Dasari S, Jiang M, Oishi N, Jacobs HK, Zeng Y, Hundal T, Rech KL, Ketterling RP, Lee JH, Eckloff BW, Yan H, Gaonkar KS, Tian S, Ye Z, Kadin ME, Sidhu J, Jiang L, Voss J, Link BK, Syrbu SI, Facchetti F, Bennani NN, Slager SL, Ordog T, Kocher JP, Cerhan JR, Ansell SM, Feldman AL.

Blood. 2019 Jun 27;133(26):2776-2789. doi: 10.1182/blood.2019000626. Epub 2019 May 17.

PMID:
31101622
8.

Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease.

Goyal G, Ravindran A, Young JR, Shah MV, Bennani NN, Patnaik MM, Nowakowski GS, Thanarajasingam G, Habermann TM, Vassallo R, Sher T, Parikh SA, Rech KL, Go RS; Mayo Clinic Histiocytosis Working Group.

Haematologica. 2020 Jan 31;105(2):348-357. doi: 10.3324/haematol.2019.219626. Print 2020.

9.

Cutaneous lesions of angioimmunoblastic T-cell lymphoma: Clinical, pathological, and immunophenotypic features.

Oishi N, Sartori-Valinotti JC, Bennani NN, Wada DA, He R, Cappel MA, Feldman AL.

J Cutan Pathol. 2019 Sep;46(9):637-644. doi: 10.1111/cup.13475. Epub 2019 May 3.

PMID:
30980412
10.

Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas.

Ellin F, Maurer MJ, Srour L, Farooq U, Jerkeman M, Connors JM, Smedby KE, Bennani NN, Ansell SM, Slack GW, Cerhan JR, Relander T, Feldman AL, Savage KJ.

Br J Haematol. 2019 Aug;186(3):e24-e27. doi: 10.1111/bjh.15859. Epub 2019 Mar 11. No abstract available.

PMID:
30859549
11.

Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms.

Goyal G, Lau D, Nagle AM, Vassallo R, Rech KL, Ryu JH, Davidge-Pitts CJ, Tobin WO, Koster MJ, Bennani NN, Shah MV, Liu MC, Go RS; Mayo Clinic Histiocytosis Working Group.

Blood. 2019 Apr 4;133(14):1607-1610. doi: 10.1182/blood-2018-12-893917. Epub 2019 Jan 29. Review. No abstract available.

PMID:
30696619
12.

Tumor Microenvironment in T-Cell Lymphomas.

Bennani NN, Ansell SM.

Cancer Treat Res. 2019;176:69-82. doi: 10.1007/978-3-319-99716-2_3.

PMID:
30596213
13.

Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker?

Thanarajasingam G, Maurer MJ, Habermann TM, Nowakowski GS, Bennani NN, Thompson CA, Cerhan JR, Witzig TE.

Nutr Cancer. 2018 Oct;70(7):1088-1090. doi: 10.1080/01635581.2018.1502328. Epub 2018 Sep 20.

PMID:
30235018
14.

Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements.

Luchtel RA, Dasari S, Oishi N, Pedersen MB, Hu G, Rech KL, Ketterling RP, Sidhu J, Wang X, Katoh R, Dogan A, Kip NS, Cunningham JM, Sun Z, Baheti S, Porcher JC, Said JW, Jiang L, Hamilton-Dutoit SJ, Møller MB, Nørgaard P, Bennani NN, Chng WJ, Huang G, Link BK, Facchetti F, Cerhan JR, d'Amore F, Ansell SM, Feldman AL.

Blood. 2018 Sep 27;132(13):1386-1398. doi: 10.1182/blood-2018-03-838524. Epub 2018 Aug 9.

15.

A population-based analysis of second primary malignancies in T-cell neoplasms.

Kommalapati A, Tella SH, Go RS, Bennani NN, Goyal G.

Br J Haematol. 2019 Apr;185(2):338-342. doi: 10.1111/bjh.15451. Epub 2018 Jul 5. No abstract available.

PMID:
29974935
16.

Genetic subtyping of breast implant-associated anaplastic large cell lymphoma.

Oishi N, Brody GS, Ketterling RP, Viswanatha DS, He R, Dasari S, Mai M, Benson HK, Sattler CA, Boddicker RL, McPhail ED, Bennani NN, Harless CA, Singh K, Clemens MW, Medeiros LJ, Miranda RN, Feldman AL.

Blood. 2018 Aug 2;132(5):544-547. doi: 10.1182/blood-2017-12-821868. Epub 2018 Jun 19. No abstract available.

17.

Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract.

Sharma A, Oishi N, Boddicker RL, Hu G, Benson HK, Ketterling RP, Greipp PT, Knutson DL, Kloft-Nelson SM, He R, Eckloff BW, Jen J, Nair AA, Davila JI, Dasari S, Lazaridis KN, Bennani NN, Wu TT, Nowakowski GS, Murray JA, Feldman AL.

Blood. 2018 May 17;131(20):2262-2266. doi: 10.1182/blood-2018-01-830968. Epub 2018 Mar 28. No abstract available.

18.

International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma.

Maurer MJ, Ellin F, Srour L, Jerkeman M, Bennani NN, Connors JM, Slack GW, Smedby KE, Ansell SM, Link BK, Cerhan JR, Relander T, Savage KJ, Feldman AL.

J Clin Oncol. 2017 Dec 20;35(36):4019-4026. doi: 10.1200/JCO.2017.73.8195. Epub 2017 Oct 26.

19.

Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma.

Hu G, Dasari S, Asmann YW, Greipp PT, Knudson RA, Benson HK, Li Y, Eckloff BW, Jen J, Link BK, Jiang L, Sidhu JS, Wellik LE, Witzig TE, Bennani NN, Cerhan JR, Boddicker RL, Feldman AL.

Leukemia. 2018 Feb;32(2):565-569. doi: 10.1038/leu.2017.309. Epub 2017 Oct 13. No abstract available.

20.

Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era.

Thanarajasingam G, Maurer MJ, Farooq U, Johnston PB, Thompson CA, Bennani NN, Ansell SM, Porrata LF, Macon WR, Syrbu SI, Cerhan JR, Habermann TM, Link BK, Witzig TE, Nowakowski GS.

Br J Haematol. 2018 Oct;183(1):149-152. doi: 10.1111/bjh.14922. Epub 2017 Sep 29. No abstract available.

21.

Peripheral T-cell lymphomas: very little good, mainly the bad and the ugly.

Bennani NN, Ansell SM.

Leuk Lymphoma. 2017 Oct;58(10):2273-2274. doi: 10.1080/10428194.2017.1326035. Epub 2017 Jun 2. No abstract available.

PMID:
28573916
22.

DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study.

Pedersen MB, Hamilton-Dutoit SJ, Bendix K, Ketterling RP, Bedroske PP, Luoma IM, Sattler CA, Boddicker RL, Bennani NN, Nørgaard P, Møller MB, Steiniche T, d'Amore F, Feldman AL.

Blood. 2017 Jul 27;130(4):554-557. doi: 10.1182/blood-2016-12-755496. Epub 2017 May 18. No abstract available.

23.

Lymphoma classification update: B-cell non-Hodgkin lymphomas.

Jiang M, Bennani NN, Feldman AL.

Expert Rev Hematol. 2017 May;10(5):405-415. doi: 10.1080/17474086.2017.1318053. Epub 2017 Apr 24. Review.

PMID:
28395545
24.

Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma.

Bennani NN, LaPlant BR, Ansell SM, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Colgan JP, Markovic SN, Nowakowski GS, Macon WR, Reeder CB, Mikhael JR, Northfelt DW, Ghobrial IM, Witzig TE.

Am J Hematol. 2017 May;92(5):448-453. doi: 10.1002/ajh.24671. Epub 2017 Mar 10.

25.

Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.

Jiang M, Bennani NN, Feldman AL.

Expert Rev Hematol. 2017 Mar;10(3):239-249. doi: 10.1080/17474086.2017.1281122. Epub 2017 Jan 29. Review.

Supplemental Content

Loading ...
Support Center